Stifel lowered the firm’s price target on Nkarta to $15 from $18 and keeps a Buy rating on the shares. The firm is anticipating multiple catalysts over the next 12-months, which should provide visibility into the longer-term viability of NKX019 and NKX101, the analyst tells investors. While these programs remain show-me stories for investors, the firm believes current valuation excludes any prospects of success.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NKTX: